Nasdaq Biotechnology Ishares ETF (IBB)

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

As Incyte has considerably outperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

Moderna has notably outperformed the broader market over the past year, yet Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Analysts are maintaining a generally positive outlook on Biogen's shares, noting recent stock strength and solid operational results.

Although Bio-Techne has underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

While Moderna has outpaced the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Our senior market strategist explains which ETFs offer exposure to high-powered biotech growth, without T. Rex-sized risk.

Regeneron Pharmaceuticals has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.